Loading clinical trials...

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD) | Clinical Trials | Clareo Health

COMPLETEDNA

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

NCT00229385•Sheba Medical Center

View on ClinicalTrials.gov

Summary

Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of Schizophrenia and OCD for at least 6 months
•Minimum score of 14 on YBOCS
•Minimum score of 60 on PANSS
•Diagnosis of Schizophrenia without OC symptoms

Exclusion Criteria

•Patients who are already being treated with ziprasidone
•Diagnosis of schizophreniform disorder
•Organic brain syndrome, mental retardation and pervasive developmental disorder
•Patients having any significantly cardiovascular illness or electrolyte imbalance

Locations (1)

Chaim Sheba Medical Center

Ramat Gan, Israel

Key Dates

Start Date

January 1, 2006

Primary Completion Date

April 1, 2008

Completion Date

April 1, 2010

Last Updated

December 31, 2013

Enrollment

ACTUAL participants

Conditions

SchizophreniaObsessive Compulsive Disorder

Interventions

Ziprasidone

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 31, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia